The changing face of acute myeloid leukemia therapeutics in the elderly population

由 Daver, Naval, Cortes, Jorge
發表在 South Asian J Cancer (2015)

Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies

由 Daver, Naval, O’Brien, Susan
發表在 Curr Hematol Malig Rep (2013)

Editorial: The Biological Landscape of Immunotherapy in AML

由 Isidori, Alessandro, Daver, Naval, Curti, Antonio
發表在 Front Oncol (2021)

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm

由 Daver, Naval, Venugopal, Sangeetha, Ravandi, Farhad
發表在 Blood Cancer J (2021)

Primary gastric chorioadenocarcinoma: a needle in a haystack

由 Shastri, Aditi, Daver, Naval G., Hayes, Teresa G.
出版 2011

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

由 Daver, Naval, Cortes, Jorge, Kantarjian, Hagop, Ravandi, Farhad
發表在 Expert Rev Hematol (2016)

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments

由 Daver, Naval, Alotaibi, Ahmad S., Bücklein, Veit, Subklewe, Marion
發表在 Leukemia (2021)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

由 Short, Nicholas J., Kantarjian, Hagop, Ravandi, Farhad, Daver, Naval
發表在 Ther Adv Hematol (2019)

Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications

由 Nazha, Aziz, Khoury, Joseph D., Rampal, Raajit K., Daver, Naval
發表在 Oncologist (2015)

Treatment of Hairy Cell Leukemia During Pregnancy: Are Purine Analogues and Rituximab Viable Therapeutic Options

由 Daver, Naval, Nazha, Aziz, Kantarjian, Hagop M., Haltom, Rodney, Ravandi, Farhad
出版 2012

Targeting FLT3 mutations in AML: review of current knowledge and evidence

由 Daver, Naval, Schlenk, Richard F., Russell, Nigel H., Levis, Mark J.
發表在 Leukemia (2019)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions

由 Samra, Bachar, Konopleva, Marina, Isidori, Alessandro, Daver, Naval, DiNardo, Courtney
發表在 Front Oncol (2020)

Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia

由 Alfayez, Mansour, Ivan, Doina, Pemmaraju, Naveen, Daver, Naval, DiNardo, Courtney D.
發表在 JCO Precis Oncol (2019)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection

由 Abbas, Hussein A, Alfayez, Mansour, Kadia, Tapan, Ravandi-Kashani, Farhad, Daver, Naval
發表在 Cancer Manag Res (2019)

EBV Induced CD30 Positive Diffuse Large B-Cell Lymphoma in a Mixed Phenotypic Leukemia patient treated with Clofarabine

由 Bhamidipati, Pavan Kumar, Jabbour, Elias, Konoplev, Sergej, Estrov, Zeev, Cortes, Jorge, Daver, Naval
出版 2012

CN-02 MYELOPATHY FOLLOWING INTRATHECAL CHEMOTHERAPY: A CASE SERIES IN ADULTS

由 Cachia, David, Kamiya-Matsouka, Carlos, Chi, Linda, Pinnix, Chelsea, Daver, Naval, Woodman, Karen
出版 2014

The emerging role of immune checkpoint based approaches in AML and MDS

由 Boddu, Prajwal, Kantarjian, Hagop, Garcia-Manero, Guillermo, Allison, James, Sharma, Padmanee, Daver, Naval
發表在 Leuk Lymphoma (2017)

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

由 Naqvi, Kiran, Daver, Naval, Pemmaraju, Naveen, Bose, Prithviraj, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
發表在 Leuk Lymphoma (2016)

Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin

由 Pankow, Jonathan D., Richard-Carpentier, Guillaume, Daver, Naval G., Glass, William F., Kala, Jaya
發表在 CEN Case Rep (2020)

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia

由 Medeiros, Bruno C., Chan, Steven M., Daver, Naval G., Jonas, Brian A., Pollyea, Daniel A.
發表在 Am J Hematol (2019)